Pancreatic ductal adenocarcinoma (PDAC) is an extremely deadly disease with a dismal long-term prognosis. Currently there is an 8% 5-year survival rate for PDAC patients, which is due in part to a lack of early detection methods (Siegal et al, 2017).
Introduction
PDAC is a type of exocrine pancreatic cancer deriving from cells that line ducts in the pancreas (Stark, A., & Eibl, G, 2015) . Advanced stages of pancreatic cancer are present in around 50% of patients due to the disease's heterogeneity of genetic mutations and lack of distinctive symptoms (Adamska et al, 2017) . The only reliably curative treatment for patients with pancreatic cancer is surgical resection; however, only precancerous or early stages of PDAC are considered resectable. In order to detect earlier stages of disease efforts must focus on identification of patients with precursors of PDAC such as pancreatic intraepithelial neoplasms (PanINs), mucinous cystic neoplasms (MCNs), and intraductal mucinous cystic neoplasms (IPMNs). Novel biomarkers are needed to detect these precursors, because the most commonly used FDA approved blood biomarker test for PDAC, the carbohydrate antigen 19-9 (CA19-9) (Becker et al, 2014) , is not routinely effective. CA19-9 is a poor screening tool for PDAC as it is expressed in low prevalence within the general population and is unreliable as a sensitive readout.
Another potential biomarker for PDAC are conventionally defined circulating tumor cells (CTCs) (Poruk et al, 2016) . CTCs are identified in the blood of patients with malignant neoplasm, but in very low numbers and rarely in healthy control samples (Poruk et al, 2016 . Therefore, CTC-based assays have failed.
A novel biomarker, identified in our laboratory, is a circulating tumor cell that is the product of tumor cell-macrophage cell fusion, referred to as circulating hybrid cell (CHC). These CHCs are of interest due to the discovery of their existence in patients with precancerous lesions as well as metastatic pancreatic cancer at levels greater than conventionally defined CTCs (Gast et al, 2018) . Although CTCs are also found across PDAC stages, CHCs exist in numbers greater in magnitude than CTCs in the metastatic setting (Gast et al, 2018) . Therefore, we hypothesize that distinct protein expression can define the various stages of pancreatic ductal adenocarcinoma.
Recognizing there are distinct morphologic differences between the different stages of pancreatic disease, identification of discrete protein profiles that define each stage of cancer can be applied to assays for early detection. Similarly, Schelitter et al identified prognostic relationships between histopathology and molecular profile based on the morphologic stratification of PDACs through mutational status of the four driver genes, KRAS, CDKN2A/p16, SMAD4 and TP53 (Jones et al, 2008) . To identify discrete disease-specific protein expression, we generated pancreatic tissue microarrays (TMA) that represented pathology across the disease continuum (normal, inflammation, PanIN, and PDAC). We then validated an extensive number of antibodies with potential differential protein expression, and applied these antibodies to the TMA. Utilizing an immunofluorescence approach, protein expression patterns were visualized from the TMA. Overall, protein expression displayed differential patterns in the epithelium across the disease axis. We identified a subset of antibodies that recognized epithelial cells, and/or cancer cells and therefore have potential to distinguish different stages of pathology across the PDAC disease axis to increase specificity of CHC's in early detection platforms. . (Gast, et al, 2018) .
Materials and Methods

Human Subjects/Ethics:
Tissue samples were collected with approved protocols according to the ethical requirements and regulations of the Oregon Health and Science University (OHSU) review board. All patients gave informed consent.
Generation of Tissue Microarray:
For tissue preparation, the selected FFPE tissues were marked for the specified tissue section utilized for the cores. A template for the TMA production was prepared with the tissues organized according to the outline: After validating antibody dilution for optimal tissue staining, the following antibodies were initially determined to have potential for staining onto the tissue Because of these antibody's discrete expression throughout the pancreatic cancer, these were the ones that have been captured so far utilizing digital microscopy. There has been some variance in the antigen retrieval step for the IHC protocol within certain antibodies, which needs to be solidified before applying the rest onto TMAs. In order to do so, different timings of antigen retrievals have been tested and will be continued alongside varying methods of the retrieval if time adjustments are deemed unnecessary.
Results
Immunohistochemistry Staining of Paraffin Embedded Formalin Fixed Pancreatic
Normal and PDAC Tissue Figure 5 : Preliminary staining across PDAC Continuum: Left is the normal tissue while right is PDAC tissue. These tissues have been costained with their respective protein markers and DAPI, which is a nuclear stain. EpCAM staining in PDAC remains specifically around the epithelium, which is also evident in H&E staining (top left of PDAC). Maspin stains cytoplasmic/membranous and secretes into extracellular space in PDAC tissue, yet is not present in normal tissue. Notch1 appears to stain more nuclear in PDAC, and more apical cytoplasm and membranous in normal tissue. ECAD stains in both PDAC and normal tissue with individualized cellular expression on the cell surface.
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Discussion
Because PDAC is such an aggressive disease, gaining the ability to detect earlier stages is critical. Currently, early detection methods are dismal and early pancreatic cancers do not often cause any symptoms (Ryan et al, 2014) . However, protein expression can change over progressive disease states. Identification of the morphological differences within disease stages alongside protein expression can help facilitate early detection.
Protein expression results have indicated increased expression of proteins such as MUC4, Bmi1, CD133, and CD166 throughout PDAC progression. These staining patterns varied across the phases of PanIN and thus display complex regulation of the epithelium across the disease axis. In this study, various antibodies were tested on PDAC tissue as well as normal tissue. Through IHC methods, we identified a subset of antibodies that displayed expression differences between PDAC tissue and normal tissue.
For specific epithelial expression, ECAD, EpCAM, and CK were highly and uniformly expressed in all epithelia. For cancer specific protein expression, Maspin, BMI1, and Glypican-1 displayed strong expression. These antibodies have showcased specificities in their expression patterns between PDAC and normal tissue, thus the process of applying them to TMA slides have begun.
ECAD was selected for the panel due to findings that loss of ECAD can generate dedifferentiation of human carcinoma cells, thus being a tumor suppressor gene (Frixen, 1991) . It has shown to express in pancreatic carcinoma cell lines. ECAD is an important molecule for cell-cell adhesion in epithelial tissues localizing on surfaces of epithelial cells within adheren junctions (Pećina-Slause, 2003) , so it would be expected to see expression from normal tissue and throughout the stages of PDAC. EpCAM is an epithelial cell adhesion molecule that has also shown prominent expression within cancer stem cells (CSC) with frequent expression in various cancers, including pancreatic cancer (Gires et al, 2009 ). Cell adhesion is a regulator of cell polarity, thus affecting proliferation and differentiation for contact inhibition (Schnell et al, 2013) . In also being an epithelial cell adhesion molecule, it is expected to be present in normal tissue to PDAC tissue. CK has been found to be abundant in epithelial cells alongside being useful markers for epithelial malignancies (Barak et al, 2004) . There has been more than 20
cytokeratins identified through releasing from proliferating or apoptotic cells, which makes CK another marker found in normal tissue and earlier stages of pancreatic cancer (Barak et al, 2004) . Maspin is a serine protease inhibitor that has displayed evidence of limiting metastases in various carcinomas, alongside expression in pancreatic cancer and not in normal pancreatic tissue (Nash et al, 2007) . Because tumor metastasis requires invasion of tumor cells, increased adhesion through Maspin can be a contributor to inhibiting tumor metastases and displaying expression in late stages PanIn and PDAC (Berardi et al, 2013) . BMI1 is a part of the polycomb protein family and controls histone ubiquitination and repression of genomic loci. It has shown upregulation in early PanINs (Schofield et al, 2015) , and should be expected to be expressed throughout all stages of pancreatic cancer. Since BMI1 represses genes that induce cell death and senescence, it is required for maintaining adult stem cells in some tissues (Park et al, 2004) . Lastly, Glypican-1 is a protein anchored to the cell membrane that has shown overexpression within pancreatic cancer (Melo et al, 2015) . They are a member of heparan sulfate proteoglycans, which are abundant on cell surfaces, extracellular matrices, and connective tissues alongside being involved in cell recognition, growth, adhesion, proliferation, differentiation, and morphogenesis (Frampton et al, 2018) . Because of these findings, alongside preliminary staining, all of these markers were selected to be applied onto TMA. In differentiating states of pancreatic epithelium, the antibody panels can be applied to patient CHCs. By quantifying CHCs and identifying a correlation between the prominence of CHCs, immunofluorescent expression, and disease stage, we can eventually create a more specific biomarker for pancreatic cancer detection. PDAC is one of the most lethal cancers with few treatments for patients, thus being the fourth common cause of cancer related deaths (Becker et al, 2014) . 80-90% present late stages of the disease that are surgically incurable (Stark et al, 2015) . Only precancerous or early stage PDAC is considered surgically resectable (Becker et al, 2014) , so the focus should be on improving methods for early detection -earlier stages are usually asymptomatic (Becker et al, 2014) . By identifying and screening high-risk populations before their symptoms arise, detection of earlier-stage lesions that may still be at a surgically-resectable stage can increase survival rates. In working to discover an early detection method involving the analysis of patient blood, a more non-invasive method can be created and utilized to determine the status of disease at much earlier states. 
